BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22041830)

  • 1. Renal failure in chronic liver disease and the hepatorenal syndrome.
    Srivastava B; Alexander GJ
    Br J Hosp Med (Lond); 2011 Sep; 72(9):497-503. PubMed ID: 22041830
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of the hepatorenal syndrome and hyponatremia in cirrhosis - part II.
    Møller S; Aagaard NK; Schmidt L; Grønbaek H; Hansen JB; Bendtsen F
    Dan Med J; 2012 Jan; 59(1):C4372. PubMed ID: 22239848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal impairment in liver diseases].
    Gerbes AL; Gülberg V
    Praxis (Bern 1994); 2006 Oct; 95(40):1535-8. PubMed ID: 17048410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
    Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
    Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The modern possibilities of the hepato-renal syndrome treatment].
    Blokhina NV; Pasechnik IN
    Khirurgiia (Mosk); 2013; (8):81-5. PubMed ID: 24344429
    [No Abstract]   [Full Text] [Related]  

  • 8. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.
    Testro AG; Angus PW
    J Gastroenterol Hepatol; 2009 Nov; 24(11):1707-9. PubMed ID: 20136956
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatorenal syndrome.
    Cárdenas A; Uriz J; Ginès P; Arroyo V
    Liver Transpl; 2000 Jul; 6(4 Suppl 1):S63-71. PubMed ID: 10915194
    [No Abstract]   [Full Text] [Related]  

  • 11. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatorenal syndrome in patients with cirrhosis.
    Moreau R
    J Gastroenterol Hepatol; 2002 Jul; 17(7):739-47. PubMed ID: 12121502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H; Chawla Y
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury and hepatorenal syndrome in cirrhosis.
    Egerod Israelsen M; Gluud LL; Krag A
    J Gastroenterol Hepatol; 2015 Feb; 30(2):236-43. PubMed ID: 25160511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.
    Alessandria C; Venon WD; Marzano A; Barletti C; Fadda M; Rizzetto M
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1363-8. PubMed ID: 12468959
    [TBL] [Abstract][Full Text] [Related]  

  • 17.  Hepatorenal syndrome: Current concepts related to diagnosis and management.
    de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
    Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: pharmacological treatment of the hepatorenal syndrome in cirrhotic patients.
    Dagher L; Patch D; Marley R; Moore K; Burroughs A
    Aliment Pharmacol Ther; 2000 May; 14(5):515-21. PubMed ID: 10792112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report.
    Vaccaro F; Giorgi A; Riggio O; De Santis A; Laviano A; Rossi-Fanelli F
    Dig Liver Dis; 2003 Jul; 35(7):503-6. PubMed ID: 12870738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.